According to data from DSM Group, the pharmaceutical market volume at distributor prices reached 2.87 trillion rubles in 2025, representing a 19% increase compared to 2024. The main driver of growth was the public sector, which expanded by 26% year-on-year, largely due to increased deliveries to healthcare institutions under contracts signed at the end of 2024, the report states.

The combined market share of the 10 largest pharmaceutical distributors remained almost unchanged over the year at just over 81%. The top three companies also remained the same:

• Puls ranked first with revenue of 468.1 billion rubles and a 16.3% market share.
• Protek took second place with 449.2 billion rubles and 15.6%.
• Katren ranked third with 371.9 billion rubles and 12.9%.

The top five was completed by Grand Capital with 218.7 billion rubles and a 7.6% share, and R-Pharm with 210.4 billion rubles and 7.3%.

The second half of the ranking includes Irwin 2, which reported revenue of 169.7 billion rubles and a 5.9% market share. The company recorded the largest growth in revenue among the top 10 distributors, increasing by 48% in monetary terms.

Positions seven through ten were occupied by:

• BSS — 133.6 billion rubles (4.7%)
• Pharmkomplekt — 133.4 billion rubles (4.6%)
• Vita Line — 103.5 billion rubles (3.6%)
• Pharmimex — 78.8 billion rubles (2.7%)

Pharmimex was the only company in the top 10 to record a decline in revenue in 2025, falling by 4%.

Supplying pharmacies remains the core business of leading distributors. As a result, consolidation in this segment is even more pronounced: the top 10 companies account for 93.1% of the market, compared to 89.5% a year earlier. The leading pharmacy distributor is Puls, with a 23.7% market share.

In contrast, market concentration in public procurement decreased to 51.7%, down from 54.8% in 2024.

“In the public sector, consolidation is progressing more slowly due to administrative barriers and the overall inertia of the market. Nevertheless, it is more convenient for the state to work with large suppliers, so the trend toward consolidation among market players continues,” analysts noted.

Among “classic” distributors in the public procurement segment (excluding manufacturers that may also win and supply tenders), Irwin 2 ranked first with a 16.9% market share. The company is actively involved in deliveries under the “Circle of Kindness” program and in the supply of orphan drugs for the treatment of hematological and neuromuscular diseases.

Source: GxP News, February 26, 2026.